Guideline #	Guideline Name	Brief Description of Guideline Change
ECG 3055	Evolent Clinical Guideline 3055 for Pomalyst (pomalidomide)	1) Updated contraindications/warnings section 2) Updated references
ECG 3056	Evolent Clinical Guideline 3056 for Iclusig (ponatinib)	Updated references
ECG 3057	Evolent Clinical Guideline 3057 for Gilotrif (afatinib)	Updated references
ECG 3058	Evolent Clinical Guideline 3058 for Fusilev/Khapzory (levoleucovorin)	Updated references
ECG 3059	Evolent Clinical Guideline 3059 for Iressa (gefitinib)	1) Updated indication section 2) Updated references
ECG 3060	Evolent Clinical Guideline 3060 for Odomzo (sonidegib)	Updated references
ECG 3061	Evolent Clinical Guideline 3061 for Besponsa (inotuzumab ozogamicin)	Updated references
ECG 3063	Evolent Clinical Guideline 3063 for Mulpleta (lusutrombopag)	Updated references
ECG 3064	Evolent Clinical Guideline 3064 for Copiktra (duvelisib)	Updated references
ECG 3065	Evolent Clinical Guideline 3065 for Piqray (alpelisib)	Updated references
ECG 3066	Evolent Clinical Guideline 3066 for Inqovi (decitabine and cedazuridine)	Updated references
ECG 3067	Evolent Clinical Guideline 3067 for Onureg (azacitidine oral)	Updated references
ECG 3068	Evolent Clinical Guideline 3068 for Topical and Intralesional Therapies Use in Non-Melanoma Skin Cancers (NMSC) and Primary Cutaneous Lymphomas	1) Updated policy numbers in indication section 2) Updated references
ECG 3069	Evolent Clinical Guideline 3069 for Fyarro (intravenous sirolimus)	1) Updated indication section 2) Updated references
ECG 3070	Evolent Clinical Guideline 3070 for Vonjo (pacritinib)	Updated references
ECG 3075	Evolent Clinical Guideline 3075 for Elahere (mirvetuximab soravtansine-gynx)	1) Updated exclusion criteria 2) Updated references
ECG 3072	Evolent Clinical Guideline 3072 for Pegasys (peginterferon alfa-2a)	1) Updated risk levels and risk level tables in indication section for myelofibrosis, polycythemia vera, and essential thrombocythemia 2) Updated references
ECG 3071	Evolent Clinical Guideline 3071 for Amtagvi (lifileucel)	1) Updated contraindications/warnings section 2) Updated references
ECG 3205	Braftovi (encorafenib)	On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024. 1) Indication was added in January 2025 2) Updated references
ECG 3204	Erbitux (Cetuximab)	On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024. 1) Indication was added in January 2025 2) Updated references

ECG 3186	Hernexeos (zongertinib)	On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test. 1) Updated indication section 2) Updated references
ECG 3093	Tazverik (tazemetostat)	On March 9, 2026, Ipsen announced it is voluntarily withdrawing Tazverik (tazemetostat) from all markets and for all of its indications, effective immediately. Ipsen's decision to withdraw is based on emerging data from the ongoing Phase Ib/III SYMPHONY-1 trial (evaluating tazemetostat in combination with lenalidomide plus rituximab (R2) vs R2 in follicular lymphoma). The Independent Data Monitoring Committee (IDMC) advised that, based on adverse events of secondary hematologic malignancies, the risks may outweigh potential benefits for patients within this treatment regimen. As a result of these data, Ipsen is withdrawing Tazverik effective immediately, including both for follicular lymphoma (FL) and epithelioid sarcoma (ES). 1) Added voluntary withdrawal verbiage to indication section 2) Will archive policy at 1-year mark of change (April 2027) 3) Updated references
ECG 3018	Opdivo and Opdivo Qvantig (nivolumab IV/SC)	On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL). 1) Hodgkin Lymphoma indication already in policy 2) Discussed but will not add for Hodgkin Lymphoma: "stage I/II unfavorable disease with B symptoms, bulky mediastinal disease and/or >10 cm adenopathy, ≥4 nodal sites, and/or ESR ≥50 mm/hr" (NCCN category 2A recommendation). Will revisit in the future if new data is published 3) Updated NSCLC indication to include use in combination with ipilimumab ± chemotherapy in metastatic NSCLC (both squamous and non-squamous) that is positive for the STK11 mutation, regardless of PD-L1 expression 4) Updated references
ECG 3155	Yervoy (ipilimumab)	1) Updated NSCLC indication to include use in combination with nivolumab ± chemotherapy in metastatic NSCLC (both squamous and non-squamous) that is positive for the STK11 mutation, regardless of PD-L1 expression 2) Updated references
ECG 3159	Keytruda and Keytruda Qlex (pembrolizumab IV/SC)	1) Removed cisplatin ineligibility verbiage and criteria from bladder cancer indication 2) Updated HCPC code 3) Updated references
ECG 3121	Padcev (enfortumab vedotin-ejfv)	1) Removed cisplatin ineligibility verbiage and criteria from bladder cancer indication 2) Updated references

ECG 3035	Enhertu (fam-trastuzumab deruxtecan-nxki)	1) Updated indication section to include use as monotherapy as adjuvant treatment in adult members with HER2-positive breast cancer that has a high risk of recurrence following neoadjuvant therapy 2) Updated references
ECG 3113	Nplate (romiplostim)	1) Updated CIT indication to restrict use in solid tumors only 2) Updated exclusion criteria 3) Updated references
ECG 3161	Reblozyl (luspatercept-aamt)	1) Changed RBC transfusion dependence in MDS indication from “2 PRBC units a month for 3 consecutive months” to “2 PRBC units/8 weeks” 2) Updated references
ECG 3074	Bone Modifying Agents	Updated HCPC codes
ECG 3134	Luteinizing Hormone Releasing Hormone (LHRH) Agonists or Antagonists	1) Added “Camcevi ETM” as a new product to all relevant sections 2) Updated references
ECG 3157	Lynozyfic (linvoseltamab-gcpt)	1) Updated HCPC code 2) Updated references
ECG 3189	Inlexzo (gemcitabine intravesical system)	1) Updated HCPC code 2) Updated references